WASHINGTON - Nearly three months later than originally anticipated, the FDA Modernization and Accountability Act of 1997 became law.
WASHINGTON - Nearly three months later than originally anticipated, the FDA Modernization and Accountability Act of 1997 became law.
President Clinton signed the final version of the bill, which the pharmaceutical industry, the Food and Drug Administration and legislators had wanted to pass by Sept. 1, on Nov. 21.
"The word that we're getting from key health care policy people is that the President's happy with it," said Jeff Trewhitt, assistant vice president of communications for the Pharmaceutical Research and Manufacturers of America.
Legislators, most notably Sen. Ted Kennedy (D-Mass.), debated the bill's finer points for months. Kennedy alone fought for 26 amendments to the bill.
The final legislation includes a five-year renewal of the Prescription Drug User Fee Act, which will allow the FDA to collect as much as $600 million in user fees from pharmaceutical companies. It also facilitates access to experimental drugs for seriously ill patients, establishes a faster track for medicines and provides pharmaceutical companies with greater incentives to develop and test medicines for children.
The new law will speed drug approval times by an additional 10 to 16 months, according to Trewhitt. When added to the 12- to 15-month improvement that the original Prescription Drug User Fee Act made possible, time spent on the average 15-year drug approval process drops significantly. "By the turn of the century, patients are going to be getting new medicines two to two-and-a-half years faster than they did at the beginning of the decade," Trewhitt said.
In addition to renewing user fee collection, the new law allows companies more leeway to disseminate scientifically valid (but not FDA-approved) information about new uses for approved drugs. It also gives the FDA more flexibility as to how it may determine the effectiveness of a drug without weakening safety standards. PR
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Unlocking value and cost savings in patient services with technology and talent
October 2nd 2024Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.